Cargando…

A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial

Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that H...

Descripción completa

Detalles Bibliográficos
Autores principales: Thor, Dominik, Pagani, Andrea, Bukowiecki, Julia, Houschyar, Khosrow S., Kølle, Stig-Frederik T., Wyles, Saranya P., Duscher, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861617/
https://www.ncbi.nlm.nih.gov/pubmed/36675398
http://dx.doi.org/10.3390/jcm12020470
_version_ 1784874886461652992
author Thor, Dominik
Pagani, Andrea
Bukowiecki, Julia
Houschyar, Khosrow S.
Kølle, Stig-Frederik T.
Wyles, Saranya P.
Duscher, Dominik
author_facet Thor, Dominik
Pagani, Andrea
Bukowiecki, Julia
Houschyar, Khosrow S.
Kølle, Stig-Frederik T.
Wyles, Saranya P.
Duscher, Dominik
author_sort Thor, Dominik
collection PubMed
description Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair.
format Online
Article
Text
id pubmed-9861617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98616172023-01-22 A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial Thor, Dominik Pagani, Andrea Bukowiecki, Julia Houschyar, Khosrow S. Kølle, Stig-Frederik T. Wyles, Saranya P. Duscher, Dominik J Clin Med Article Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair. MDPI 2023-01-06 /pmc/articles/PMC9861617/ /pubmed/36675398 http://dx.doi.org/10.3390/jcm12020470 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thor, Dominik
Pagani, Andrea
Bukowiecki, Julia
Houschyar, Khosrow S.
Kølle, Stig-Frederik T.
Wyles, Saranya P.
Duscher, Dominik
A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title_full A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title_fullStr A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title_full_unstemmed A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title_short A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
title_sort novel hair restoration technology counteracts androgenic hair loss and promotes hair growth in a blinded clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861617/
https://www.ncbi.nlm.nih.gov/pubmed/36675398
http://dx.doi.org/10.3390/jcm12020470
work_keys_str_mv AT thordominik anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT paganiandrea anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT bukowieckijulia anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT houschyarkhosrows anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT køllestigfrederikt anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT wylessaranyap anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT duscherdominik anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT thordominik novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT paganiandrea novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT bukowieckijulia novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT houschyarkhosrows novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT køllestigfrederikt novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT wylessaranyap novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial
AT duscherdominik novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial